Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate.
Jee Won SuhSeong Yong ParkChang Young LeeSeung Hwan SongDae Joon KimHyo Chae PaikKyoung Young ChungMin Hee HongHye Ryun KimByoung Chul ChoJin Gu LeePublished in: PloS one (2019)
Neoadjuvant therapy does not significantly influence the R0 resection rate or overall survival relative to primary surgery. Nevertheless, it may by useful for patients planning surgical resection because it significantly reduces the presurgical tumor volume and extent of invasion.
Keyphrases
- rectal cancer
- end stage renal disease
- lymph node
- locally advanced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- minimally invasive
- prognostic factors
- deep learning
- peritoneal dialysis
- squamous cell carcinoma
- convolutional neural network
- optical coherence tomography
- coronary artery disease
- mesenchymal stem cells
- radiation therapy
- cell migration
- surgical site infection
- cell therapy